These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26954340)

  • 21. Reporting Compliance of Stroke Trials: Cross-Sectional Analysis.
    Malhotra K; Rayi A; Khunger M; Thompson S; Liebeskind DS
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):1472-1480. PubMed ID: 28412315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for postmarketing surveillance of drugs for rare diseases.
    Kesselheim AS; Gagne JJ
    Clin Pharmacol Ther; 2014 Mar; 95(3):265-8. PubMed ID: 24193169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Regulations concerning data transparency- a comparison between the USA and Europe].
    Quack C
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(3):183-8. PubMed ID: 21530907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transparency in ovarian cancer clinical trial results: ClinicalTrials.gov versus PubMed, Embase and Google scholar.
    Roberto A; Radrezza S; Mosconi P
    J Ovarian Res; 2018 Apr; 11(1):28. PubMed ID: 29636080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies registered in non-ClinicalTrials.gov accounted for an increasing proportion of protocol registrations in medical research.
    Banno M; Tsujimoto Y; Kataoka Y
    J Clin Epidemiol; 2019 Dec; 116():106-113. PubMed ID: 31521723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of the Registration in the Clinical Research Information Service.
    Choi EK; Kim MJ; Lim NK; Park HY
    J Korean Med Sci; 2016 Jan; 31(1):1-8. PubMed ID: 26770030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sponsorship and design characteristics of trials registered in ClinicalTrials.gov.
    Roumiantseva D; Carini S; Sim I; Wagner TH
    Contemp Clin Trials; 2013 Mar; 34(2):348-55. PubMed ID: 23380028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using the Internet to recruit patients for epilepsy trials: results of a New Zealand pilot study.
    Bergin PS; Ip T; Sheehan R; Frith RW; Sadleir LG; McGrath N; Ranta A; Walker EB
    Epilepsia; 2010 May; 51(5):868-73. PubMed ID: 19889017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focusing on rare diseases in China: are we there yet?
    Yang L; Su C; Lee AM; Bai HX
    Orphanet J Rare Dis; 2015 Nov; 10():142. PubMed ID: 26525984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P
    Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov.
    Hee SW; Willis A; Tudur Smith C; Day S; Miller F; Madan J; Posch M; Zohar S; Stallard N
    Orphanet J Rare Dis; 2017 Mar; 12(1):44. PubMed ID: 28253932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to Overcome Scientific Standstill for Very Rare Diseases: Clinical Trials or Clinical Registries?
    Körholz D; Schneider D; von Kries R; Mauz-Körholz C; Göbel U
    Klin Padiatr; 2015 Nov; 227(6-7):303-4. PubMed ID: 26600174
    [No Abstract]   [Full Text] [Related]  

  • 34. [Difficulties with conducting clinical trials in France].
    Zannad F; Plétan Y
    Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of control groups in cardiovascular clinical trials: An analysis of ClinicalTrials.gov from 2009 through 2019.
    Zheutlin AR; Caldwell DJ; Al Danaf J; Shah RU
    Am Heart J; 2021 Apr; 234():133-135. PubMed ID: 33347871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tactics of large randomized trials.
    Slobogean GP; Sprague S; Bhandari M
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():19-23. PubMed ID: 22810442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The randomized controlled trial: basic considerations.
    Duffy ME
    Clin Nurse Spec; 2006; 20(2):62-4. PubMed ID: 16609277
    [No Abstract]   [Full Text] [Related]  

  • 39. Blinded sample size recalculation in clinical trials incorporating historical data.
    Hees K; Kieser M
    Contemp Clin Trials; 2017 Dec; 63():2-7. PubMed ID: 28735110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.